Compare Eli Lilly And Co (LLY) vs Oatly Group AB - ADR (OTLY) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

OTLY trades at $9.81, down 2.29% on the day, with a bullish technical signal from moving averages. Revenue grew to $862.46M in 2025, but net losses persist at -$152.77M. Cash burn remains a concern with negative operating cash flow of -$23.72M. The company announced Q2 2026 results for July 22, 2026, and continues brand partnerships like the Nespresso iced coffee collaboration.

Outlook is mixed: strong brand and revenue growth offer potential, but profitability challenges and high debt-to-asset ratio of 66.53% pose significant risks. Analyst consensus is divided with 44% buy ratings, yet cash runway constraints highlighted by Seeking Alpha on 2026-05-14 require careful monitoring for equity investors.